LT4477B - Fluoksetino enterinės piliulės - Google Patents

Fluoksetino enterinės piliulės Download PDF

Info

Publication number
LT4477B
LT4477B LT98-058A LT98058A LT4477B LT 4477 B LT4477 B LT 4477B LT 98058 A LT98058 A LT 98058A LT 4477 B LT4477 B LT 4477B
Authority
LT
Lithuania
Prior art keywords
fluoxetine
layer
enteric
core
hpmcas
Prior art date
Application number
LT98-058A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT98058A (en
Inventor
Neil Robert Anderson
Roger Garrick Harrison
Daniel Frederick Lynch
Peter Lloyd Oren
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4477(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT98058A publication Critical patent/LT98058A/xx
Publication of LT4477B publication Critical patent/LT4477B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LT98-058A 1997-05-29 1998-04-22 Fluoksetino enterinės piliulės LT4477B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (2)

Publication Number Publication Date
LT98058A LT98058A (en) 1998-10-26
LT4477B true LT4477B (lt) 1999-03-25

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
LT98-058A LT4477B (lt) 1997-05-29 1998-04-22 Fluoksetino enterinės piliulės

Country Status (46)

Country Link
US (3) US5910319A (cs)
JP (1) JP3210288B2 (cs)
KR (1) KR100549473B1 (cs)
CN (2) CN1161109C (cs)
AR (1) AR011728A1 (cs)
AT (1) AT408068B (cs)
AU (1) AU726690B2 (cs)
BE (1) BE1011925A3 (cs)
BR (1) BR9801989A (cs)
CA (1) CA2234826C (cs)
CH (1) CH693018A5 (cs)
CO (1) CO4940407A1 (cs)
CZ (1) CZ290582B6 (cs)
DE (1) DE19823940B4 (cs)
DK (1) DK176776B1 (cs)
ES (1) ES2161574B1 (cs)
FI (1) FI119971B (cs)
FR (1) FR2763846B1 (cs)
GB (1) GB2325623B (cs)
GR (1) GR980100188A (cs)
HK (1) HK1034902A1 (cs)
HU (1) HUP9800882A3 (cs)
ID (1) ID20343A (cs)
IL (1) IL124073A (cs)
IT (1) ITMI980908A1 (cs)
LT (1) LT4477B (cs)
LU (1) LU90245B1 (cs)
LV (1) LV12176B (cs)
MY (1) MY118139A (cs)
NL (1) NL1009259C2 (cs)
NO (1) NO317743B1 (cs)
NZ (1) NZ330192A (cs)
PE (1) PE75399A1 (cs)
PL (1) PL192293B1 (cs)
PT (1) PT102152B (cs)
RO (1) RO120043B1 (cs)
RS (1) RS49827B (cs)
RU (1) RU2164405C2 (cs)
SE (1) SE522914C2 (cs)
SG (1) SG72805A1 (cs)
SI (1) SI9800128B (cs)
SV (1) SV1998000052A (cs)
TR (1) TR199800937A2 (cs)
TW (1) TWI239838B (cs)
UA (1) UA48193C2 (cs)
ZA (1) ZA983173B (cs)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
IL148159A0 (en) 1999-09-03 2002-09-12 Lilly Co Eli Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2002361495A1 (en) * 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
WO2005065726A1 (en) * 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
JP4277904B2 (ja) * 2004-04-30 2009-06-10 アステラス製薬株式会社 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
EP1863782A1 (en) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
KR20080094837A (ko) * 2006-02-24 2008-10-24 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 약학 조성물
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
EP1919467A2 (en) * 2006-05-22 2008-05-14 Teva Pharmaceutical Industries Ltd Duloxetine hydrochloride delayed release formulations
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
BRPI0714915A2 (pt) * 2006-07-28 2013-05-28 Reddys Lab Ltd Dr composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
PL2317852T3 (pl) 2008-07-16 2015-05-29 Richter Gedeon Nyrt Preparaty farmaceutyczne zawierające ligandy receptora dopaminy
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
EP2477614A2 (en) * 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
ES2728850T3 (es) 2012-05-02 2019-10-29 Capsugel Belgium Nv Dispersiones acuosas de acetato acetato succinato de hidroxipropilmetilcelulosa (HPMCAS)
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
ES2706994T3 (es) 2012-09-03 2019-04-02 Daiichi Sankyo Co Ltd Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR20170005833A (ko) 2014-05-20 2017-01-16 다우 글로벌 테크놀로지스 엘엘씨 부분적으로 중화된 에스테르화 셀룰로오스 에테르를 포함하는 분산물
WO2015179073A1 (en) * 2014-05-20 2015-11-26 Dow Global Technologies Llc Capsule shells comprising an esterified cellulose ether
WO2015187874A1 (en) * 2014-06-07 2015-12-10 Structure-Ase, Inc. A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
MA52457A (fr) * 2017-04-13 2021-03-10 Chase Therapeutics Corp Combinaison pharmaceutique et son utilisation pour le traitement de synucléinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4444778A (en) 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4626549A (en) 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
WO1992013452A1 (en) 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
US5356934A (en) 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
EP0693281A2 (en) 1994-07-20 1996-01-24 Lilly S.A. Fluoxetine Pharmaceutical formulations
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
AU2154892A (en) * 1991-05-07 1992-12-21 Dynagen, Inc. A controlled, sustained release delivery system for treating drug dependency
CA2132012C (en) * 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
EP0726761B1 (en) * 1993-11-03 2001-01-10 ISOMED, Inc. Microparticular pharmaceutical compositions in micellar form
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4626549A (en) 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4444778A (en) 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US5356934A (en) 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
WO1992013452A1 (en) 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
EP0693281A2 (en) 1994-07-20 1996-01-24 Lilly S.A. Fluoxetine Pharmaceutical formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENAZZI F, MAZZOLI M.: "Fluoxetine-induced sexual dysfunction: a dose-dependent effect?", PHARMACOPSYCHIATRY, 1994, pages 246
BURKE ET AL.: "Weekly Fluoxetine Controls Symptoms of Depression", PSYCHOPHARMACOLOGY BULLETIN, 1995, pages 524
MONTGOMERY D B ET AL.: "Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts", EUR ARCH PSYCHIATRY CLIN NEUROSCI, 1994, pages 211
ROBERTSON DW ET AL.: "Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor", J MED CHEM., 1988, pages 1412, XP000568845, DOI: doi:10.1021/jm00402a027

Also Published As

Publication number Publication date
TR199800937A3 (tr) 1999-10-21
CZ114398A3 (cs) 1998-12-16
KR19980086622A (ko) 1998-12-05
AR011728A1 (es) 2000-08-30
IL124073A (en) 2002-02-10
US5985322A (en) 1999-11-16
SE9801336D0 (sv) 1998-04-17
PT102152B (pt) 2000-09-29
PT102152A (pt) 1998-12-31
NL1009259C2 (nl) 1998-12-01
RU2164405C2 (ru) 2001-03-27
DK176776B1 (da) 2009-08-10
LT98058A (en) 1998-10-26
DE19823940B4 (de) 2010-04-29
IE980284A1 (en) 2000-07-12
ATA93198A (de) 2001-01-15
FR2763846B1 (fr) 2001-05-18
GB9807939D0 (en) 1998-06-10
CZ290582B6 (cs) 2002-08-14
PL326134A1 (en) 1998-12-07
LU90245A1 (cs) 1998-11-30
NZ330192A (en) 1999-08-30
SI9800128B (sl) 2000-04-30
LV12176B (en) 1999-03-20
FI119971B (fi) 2009-05-29
NO982197L (no) 1998-11-30
LV12176A (lv) 1998-12-20
CN1161109C (zh) 2004-08-11
CA2234826A1 (en) 1998-11-29
GB2325623B (en) 1999-04-14
FI980846A (fi) 1998-11-30
ITMI980908A1 (it) 1999-10-28
RS49827B (sr) 2008-08-07
DE19823940A1 (de) 1998-12-03
NO982197D0 (no) 1998-05-14
SG72805A1 (en) 2000-05-23
LU90245B1 (fr) 2002-07-31
ZA983173B (en) 1999-10-15
HUP9800882A3 (en) 2000-07-28
KR100549473B1 (ko) 2006-03-23
AU6904898A (en) 1998-12-03
US5910319A (en) 1999-06-08
UA48193C2 (uk) 2002-08-15
BR9801989A (pt) 2000-02-08
BE1011925A3 (fr) 2000-03-07
CO4940407A1 (es) 2000-07-24
SV1998000052A (es) 1999-03-16
ES2161574A1 (es) 2001-12-01
CN1212834C (zh) 2005-08-03
GB2325623A (en) 1998-12-02
ID20343A (id) 1998-12-03
AT408068B (de) 2001-08-27
AU726690B2 (en) 2000-11-16
JPH10330253A (ja) 1998-12-15
TR199800937A2 (xx) 1999-10-21
JP3210288B2 (ja) 2001-09-17
NO317743B1 (no) 2004-12-13
MY118139A (en) 2004-09-30
SE9801336L (sv) 1998-11-30
CN1200924A (zh) 1998-12-09
FR2763846A1 (fr) 1998-12-04
YU16598A (en) 1999-11-22
FI980846A0 (fi) 1998-04-16
HU9800882D0 (en) 1998-05-28
CH693018A5 (de) 2003-01-31
CA2234826C (en) 2000-12-19
CN1285189A (zh) 2001-02-28
PL192293B1 (pl) 2006-09-29
SE522914C2 (sv) 2004-03-16
ES2161574B1 (es) 2002-06-16
PE75399A1 (es) 1999-08-17
HK1034902A1 (en) 2001-11-09
GR980100188A (el) 1999-01-29
USRE39030E1 (en) 2006-03-21
HUP9800882A2 (hu) 2000-03-28
SI9800128A (sl) 1999-02-28
TWI239838B (en) 2005-09-21
RO120043B1 (ro) 2005-08-30

Similar Documents

Publication Publication Date Title
LT4477B (lt) Fluoksetino enterinės piliulės
RU2147231C1 (ru) Кишечные гранулы дульоксетина
AU771064B2 (en) Opioid analgesics With Controlled Active Substance Release
US6254891B1 (en) Extended release acetaminophen
SK50442006A3 (sk) Pelety obsahujúce hydrochlorid venlafaxínu
MXPA98003636A (es) Granulos entericos de fluoxetina
IE83510B1 (en) Fluoxetine enteric pellets

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20180422